CJC-1295 – With DAC 5mg

What is CJC-1295 – With DAC (5mg)?

CJC-1295 is a synthetic peptide analog of growth hormone-releasing hormone (GHRH). It has been modified to extend the biological activity of native GHRH by incorporating a Drug Affinity Complex (DAC), which allows reversible binding to serum albumin. This modification has been studied for its potential to prolong circulating half-life in experimental models. CJC-1295 contains a modified amino acid sequence derived from GHRH (1–29) and has been studied for its effects on growth hormone signaling dynamics in controlled research environments.

What are the key features of CJC-1295 – With DAC (5mg)?

CJC-1295 – With DAC (5mg) is typically presented as a lyophilized peptide intended for laboratory research applications. The DAC modification has been studied for its potential to extend the circulating half-life of the peptide in experimental models. Key features include:

• Peptide class: Synthetic GHRH analog with DAC modification
• Purity: ≥98% purity confirmed by HPLC
• Chemical Formula: C₁₅₂H₂₅₂N₄₄O₄₂
• Molecular Weight: 3647.2 g/mol
• Identity verification: Mass spectrometry (MS) for molecular confirmation
• Format: Lyophilized powder (verify exact presentation with supplier documentation)
• DAC modification studied for its potential to extend circulating half-life in experimental models
• Compliance: For laboratory research use only

How is CJC-1295 – With DAC (5mg) synthesized?

CJC-1295 is produced using solid-phase peptide synthesis (SPPS), where protected amino acids are sequentially coupled to generate the modified GHRH fragment. The DAC component is chemically linked to the peptide, allowing reversible attachment to circulating albumin in research models. Following synthesis, purification is performed using high-performance liquid chromatography (HPLC) to achieve the desired purity. Mass spectrometry (MS) and related analytical techniques are used to verify molecular identity and ensure batch-to-batch consistency.

What is CJC-1295 – With DAC (5mg) being studied for? What are its possible benefits?

CJC-1295 has been studied in clinical research for its effects on growth hormone (GH) and insulin-like growth factor-1 (IGF-1) levels. Early-phase human studies have evaluated its pharmacokinetics and impact on endogenous hormone pulsatility. Research areas include:

• Growth hormone secretion dynamics
• IGF-1 modulation
• Endocrine signaling stability
• Protein metabolism pathways

Possible biological effects under investigation include sustained stimulation of GH release and prolonged elevation of IGF-1 concentrations in experimental settings. These findings are based on research and do not establish therapeutic outcomes. Ongoing studies continue to evaluate safety, pharmacokinetics, and mechanistic properties.

How does CJC-1295 – With DAC (5mg) work in research studies?

CJC-1295 mimics endogenous GHRH activity by stimulating the release of growth hormone from the anterior pituitary, rather than supplying exogenous hormone. The DAC modification enables the peptide to bind reversibly to circulating albumin, slowing its renal clearance and enzymatic breakdown. This results in prolonged systemic exposure in experimental models. Research has reported sustained increases in GH and IGF-1 levels following administration, reflecting extended biological activity compared to shorter-acting GHRH analogs.

What dosing information exists for CJC-1295 – With DAC (5mg)?

Published clinical research has evaluated CJC-1295 in single-dose and repeated-dose studies. Early human trials reported subcutaneous administration in microgram-per-kilogram ranges, including doses such as 30–60 µg/kg in controlled research settings. These studies assessed pharmacokinetic parameters and hormonal response over several days. Preclinical investigations have also explored dose-dependent endocrine responses in animal models. No standardized dosing guidelines exist for clinical or therapeutic use. All available dosing information is derived from experimental research, and CJC-1295 is not approved for medical treatment.

How should CJC-1295 – With DAC (5mg) be stored and handled?

CJC-1295 should be stored at –20 °C, protected from light and moisture to preserve peptide stability. Lyophilized peptide preparations typically exhibit extended stability at frozen temperatures when stored in airtight containers. Upon reconstitution with a suitable laboratory solvent, solutions are generally stored at 2–8 °C and used within a defined validation period, determined by laboratory protocols. Repeated freeze–thaw cycles should be avoided, as they may compromise structural integrity. Stability data may vary depending on handling conditions and buffer composition.

Where can I read more research about CJC-1295 – With DAC (5mg)?

1. Teichman SL, Neale A, Lawrence B, Gagnon C, Castaigne JP, Frohman LA. Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. J Clin Endocrinol Metab. 2006;91(3):799-805. doi:10.1210/jc.2005-1536
2. Jetté L, Léger R, Thibaudeau K, et al. Human growth hormone-releasing factor (hGRF)1-29-albumin bioconjugates activate the GRF receptor on the anterior pituitary in rats: identification of CJC-1295 as a long-lasting GRF analog. Endocrinology. 2005;146(7):3052-3058. doi:10.1210/en.2004-1286
3. Frohman LA, Downs TR, Williams TC, Heimer EP, Pan YC, Felix AM. Rapid enzymatic degradation of growth hormone-releasing hormone by plasma in vitro and in vivo to a biologically inactive product cleaved at the NH2 terminus. J Clin Invest. 1986;78(4):906-913. doi:10.1172/JCI112679
4. Thorner MO. The discovery of growth hormone-releasing hormone. J Neuroendocrinol. 2008;20(6):647-652. doi:10.1111/j.1365-2826.2008.01739.x

Compliance Statement

This product is intended for laboratory research use only and is not approved for human or veterinary use.